rs1545119
Variant names:
Your query was ambiguous. Multiple possible variants found:
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_000137.4(FAH):c.553+33A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.728 in 1,610,242 control chromosomes in the GnomAD database, including 428,100 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.73 ( 40974 hom., cov: 29)
Exomes 𝑓: 0.73 ( 387126 hom. )
Consequence
FAH
NM_000137.4 intron
NM_000137.4 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.209
Genes affected
FAH (HGNC:3579): (fumarylacetoacetate hydrolase) Predicted to enable fumarylacetoacetase activity. Predicted to be involved in L-phenylalanine catabolic process; homogentisate catabolic process; and tyrosine catabolic process. Predicted to act upstream of or within arginine catabolic process. Located in extracellular exosome. Implicated in tyrosinemia type I. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.96).
BP6
Variant 15-80168182-A-G is Benign according to our data. Variant chr15-80168182-A-G is described in ClinVar as [Benign]. Clinvar id is 255282.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.854 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FAH | NM_000137.4 | c.553+33A>G | intron_variant | Intron 6 of 13 | ENST00000561421.6 | NP_000128.1 | ||
FAH | NM_001374377.1 | c.553+33A>G | intron_variant | Intron 7 of 14 | NP_001361306.1 | |||
FAH | NM_001374380.1 | c.553+33A>G | intron_variant | Intron 7 of 14 | NP_001361309.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.734 AC: 111294AN: 151576Hom.: 40947 Cov.: 29
GnomAD3 genomes
AF:
AC:
111294
AN:
151576
Hom.:
Cov.:
29
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.731 AC: 183153AN: 250622Hom.: 67616 AF XY: 0.738 AC XY: 100022AN XY: 135502
GnomAD3 exomes
AF:
AC:
183153
AN:
250622
Hom.:
AF XY:
AC XY:
100022
AN XY:
135502
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.727 AC: 1060366AN: 1458552Hom.: 387126 Cov.: 33 AF XY: 0.730 AC XY: 530235AN XY: 725878
GnomAD4 exome
AF:
AC:
1060366
AN:
1458552
Hom.:
Cov.:
33
AF XY:
AC XY:
530235
AN XY:
725878
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.734 AC: 111373AN: 151690Hom.: 40974 Cov.: 29 AF XY: 0.734 AC XY: 54342AN XY: 74066
GnomAD4 genome
AF:
AC:
111373
AN:
151690
Hom.:
Cov.:
29
AF XY:
AC XY:
54342
AN XY:
74066
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
2836
AN:
3478
ClinVar
Significance: Benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: not provided
- -
Mar 03, 2015
GeneDx
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
Tyrosinemia type I Benign:2
Jul 26, 2019
Natera, Inc.
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing
- -
Jul 01, 2021
Genome-Nilou Lab
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
not specified Benign:1
-
PreventionGenetics, part of Exact Sciences
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at